Anticoagulants Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

The Anticoagulants market is segmented By Drug Class (Novel oral anticoagulants (NOACs), Heparin and Low Molecular Weight Heparin (LMWH), and Vitamin k Antagonist), By Application and Geography.

Anticoagulants Market Snapshot

Oral Anticoagulants Market Size
Study Period: 2018 - 2026
Base Year: 2021
Fastest Growing Market: Asia Pacific
Largest Market: North America
CAGR: 9.41 %
Anticoagulats Market Major Players

Need a report that reflects how COVID-19 has impacted this market and its growth?

Market Overview

The Anticoagulants Market is expected to register a CAGR of 9.41% during the forecast period. Anticoagulants are used to treat and prevent blood clots which can block blood vessels (an artery or a vein) that can lead to serious complications as the clot disrupts the flow of blood to important organs and can result in heart attack and stroke.

A blood clot is a seal created by the blood to stop bleeding from wounds. Most prescribed anticoagulant is warfarin. Some of the newer types of anticoagulants are edoxaban, apixaban, dabigatran, and rivaroxaban.

According to the World Health Organization (WHO), globally cardiovascular diseases (CVDs) are the number 1 cause of death, an estimated 17.9 million each year suffer from cardiovascular diseases. Four out of 5 cardiovascular deaths are due to strokes and heart attacks, and one-third of deaths occur prematurely in people under 70 years of age.

Furthermore, increasing cases of chronic diseases, unhealthy lifestyles adopted by individuals, and growing adoption of novel oral anticoagulants (NOACs) are the key driving factors in anticoagulants market.

Scope of the Report

As per the scope of the report, anticoagulants are medicines used to treat and prevent blood clots that may occur in blood vessels. Anticoagulants Market is segmented By Drug Class, Application, and Geography.

By Drug Class
Novel Oral Anticoagulants (NOACs)
Heparin and Low Molecular Weight Heparin (LMWH)
Vitamin K Antagonist
By Application
Atrial Fibrillation/Myocardial Infarction (Heart Attack)
Deep Vein Thrombosis (DVT)
Pulmonary Embolism
Other Applications
North America
United States
United Kingdom
Rest of Europe
South Korea
Rest of Asia-Pacific
Middle-East and Africa
South Africa
Rest of Middle-East and Africa
South America
Rest of South America

Report scope can be customized per your requirements. Click here.

Key Market Trends

Novel Oral Anticoagulants (NOACs) Segment is Expected to Hold Significant Market Share in the Anticoagulants Market

Novel Oral Anticoagulants (NOACs) segment holds a significant market share in the anticoagulants market and is anticipated to show a similar trend over the forecast period owing to the growing adoption of the novel oral anticoagulants (NOACs) in developing countries and high preference of NOACs over the warfarin. Novel oral anticoagulants (NOACs) are a new class of anticoagulant drugs. Moreover, these are safe (lower incidence of major bleeding), convenient to use, no interactions with food, and shorter half-life. Some of the NOACs include dabigatran, rivaroxaban, apixaban, and edoxaban. These can be used in the prevention and treatment of atrial fibrillation/myocardial infarction, deep vein thrombosis (DVT) and pulmonary embolism. 

According to the Centers for Disease Control and Prevention (CDC), each year in the United States approximately 900,000 people ((1 to 2 per 1,000 population) could be affected with deep vein thrombosis. Moreover, about 60,000-100,000 Americans die of deep vein thrombosis. The increasing incidences of cardiovascular disorders, venous thromboembolism (VTE), and technological advancements in the development of novel products are the key driving factors in the novel oral anticoagulants (NOACs) segment.

Oral Anticoagulants Market Trends

North America Holds the Largest Share by Revenue in the Market

North America is expected to hold a major market share in the global anticoagulants market due to the high demand for innovative products, and the increasing prevalence of cardiovascular disorders in this region. According to the American Heart Association Research, approximately 2,300 Americans die due to cardiovascular diseases each day, an average of one death every 38 seconds. Furthermore, the presence of top pharma and biotech companies that are involved in the development of therapeutics and the presence of well-established healthcare infrastructure is also fueling the growth of the overall regional market to a large extent.

Anticoagulats Market Growth

Competitive Landscape

The Anticoagulants Market is fragmented competitive and consists of several major players. Some of the major players operating in the market include Johnson & Johnson, Bayer AG, Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company, Daiichi Sankyo Company, GlaxoSmithKline Plc, Aspen Holdings, Sanofi, Pfizer, Inc and Portola Pharmaceuticals, Inc.

Table of Contents


    1. 1.1 Study Assumptions

    2. 1.2 Scope of the Study




    1. 4.1 Market Overview

    2. 4.2 Market Drivers

      1. 4.2.1 Increasing Cases of Chronic Diseases

      2. 4.2.2 Technological Advancements in Development of Anticoagulant Products

      3. 4.2.3 Growing Adoption of Novel Oral Anticoagulants (NOACs)

    3. 4.3 Market Restraints

      1. 4.3.1 Stringent Government Regulations

      2. 4.3.2 Side Effects Associated with Treatment

    4. 4.4 Porter's Five Force Analysis

      1. 4.4.1 Threat of New Entrants

      2. 4.4.2 Bargaining Power of Buyers/Consumers

      3. 4.4.3 Bargaining Power of Suppliers

      4. 4.4.4 Threat of Substitute Products

      5. 4.4.5 Intensity of Competitive Rivalry


    1. 5.1 By Drug Class

      1. 5.1.1 Novel Oral Anticoagulants (NOACs)

      2. 5.1.2 Heparin and Low Molecular Weight Heparin (LMWH)

      3. 5.1.3 Vitamin K Antagonist

    2. 5.2 By Application

      1. 5.2.1 Atrial Fibrillation/Myocardial Infarction (Heart Attack)

      2. 5.2.2 Deep Vein Thrombosis (DVT)

      3. 5.2.3 Pulmonary Embolism

      4. 5.2.4 Other Applications

    3. 5.3 Geography

      1. 5.3.1 North America

        1. United States

        2. Canada

        3. Mexico

      2. 5.3.2 Europe

        1. Germany

        2. United Kingdom

        3. France

        4. Italy

        5. Spain

        6. Rest of Europe

      3. 5.3.3 Asia-Pacific

        1. China

        2. Japan

        3. India

        4. Australia

        5. South Korea

        6. Rest of Asia-Pacific

      4. 5.3.4 Middle-East and Africa

        1. GCC

        2. South Africa

        3. Rest of Middle-East and Africa

      5. 5.3.5 South America

        1. Brazil

        2. Argentina

        3. Rest of South America


    1. 6.1 Company Profiles

      1. 6.1.1 Johnson & Johnson

      2. 6.1.2 Bayer AG

      3. 6.1.3 Boehringer Ingelheim GmbH

      4. 6.1.4 Bristol-Myers Squibb Company

      5. 6.1.5 Daiichi Sankyo Company

      6. 6.1.6 Abbott Laboratories

      7. 6.1.7 Aspen Holdings

      8. 6.1.8 Sanofi

      9. 6.1.9 Pfizer, Inc

      10. 6.1.10 Alexion Pharmaceuticals Inc. 

      11. 6.1.11 Leo Pharma AS 

      12. 6.1.12 Dr. Reddy’s Laboratories 

    2. *List Not Exhaustive

**Competitive Landscape covers- Business Overview, Financials, Products and Strategies, and Recent Developments

You can also purchase parts of this report. Do you want to check out a section wise price list?

Frequently Asked Questions

The Anticoagulants Market market is studied from 2018 - 2026.

The Anticoagulants Market is growing at a CAGR of 9.41% over the next 5 years.

Asia Pacific is growing at the highest CAGR over 2021- 2026.

North America holds highest share in 2020.

Johnson & Johnson, Bayer AG, Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company, Daiichi Sankyo Company are the major companies operating in Anticoagulants Market.

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Please enter a valid email id!

Please enter a valid message!